Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus platinum doublet chemotherapy as neoadjuvant therapy in resectable stage II–IIIA squamous NSCLC
ChiCTR2100045698Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Pulmonary squamous cell carcinoma, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Major pathological response rate. Started May 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2100045698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045698.